/
Partial agonist at nicotinic acetyl Partial agonist at nicotinic acetyl

Partial agonist at nicotinic acetyl - PowerPoint Presentation

olivia-moreira
olivia-moreira . @olivia-moreira
Follow
387 views
Uploaded On 2016-11-02

Partial agonist at nicotinic acetyl - PPT Presentation

choline Receptors 3 Therapeutic use in smoking cessation and neurodegenerational diseases Asymmetric Synthesis of the Lupin Alkaloids Cytisine Sparteine Anagyrine and ID: 483857

asymmetric synthesis hydrogenation cytisine synthesis asymmetric cytisine hydrogenation sparteine reduction thermopsine anagyrine chem compound highly completion successful alkaloids therapeutic

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Partial agonist at nicotinic acetyl" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Partial agonist at nicotinic acetyl

choline

Receptors.3 Therapeutic use in: smoking cessation and neurodegenerational diseases.

Asymmetric Synthesis of the Lupin Alkaloids:(-)-Cytisine, (-)-Sparteine, (+)-Anagyrine, and (+)-Thermopsine

Results - HydrogenationThis successful reduction was highly enantioselective with 94.5 % ee and 89 % conversion under optimised conditions.Some over reduction of the pyridone ring was observed (~11 % conv.) ee’s were determined by HPLC

Future Work - Completion of the SynthesisFrom compound 7, completion of the synthesis is known.4 This compound could potentially be reached by the regioselective reduction of imide 6.

References:

PhD AIMS To complete the asymmetric synthesis of: (-)-cytisine, (-)-sparteine, (+)-anagyrine, and (+)-thermopsine To Synthesise desirable cytisine derivatives for pharmaceutical research

1. Burk, M. F.; Gross, J. P. J. Am. Chem. Soc., 19952. Heller, D.; Holz, J. J. Org. Chem. 2001, 66, 68163. Stead, D.; O’Brien, P.; Sanderson, A. J. Organic Letters, 2005, 7, 44594. Gallagher, T.; Gray, D. Angew. Chem. Int. Ed., 2006, 45, 2419

Alexander Bisset1, Martin Wills1, Teyrnon Jones2University of Warwick; 2) AstraZeneca R&D, Charnwood

Background -

Asymmetric Alkene HydrogenationHydrogenation of N-acylamino acrylates (1) is highly selective with catalysts such as [Rh(DuPHOS)COD]BF4 (2)1.Mechanistically, hydrogenation is likely to proceed through the co-ordination mode 32This gave the precedent for the hydrogenation of 5 - a potential (-)-cytisine precursor, which could potentially be reduced in the same way (4).

(-)-cytisine

(-)-sparteine

(+)-anagyrine

(+)-thermopsine

Grounds

for Synthesis

Used in catalysis

as a

c

hiral

bidentate

ligand

4

Although asymmetric syntheses of the alkaloids exist, none have proceeded via asymmetric hydrogenation.

A preliminary study by Akira Shiibashi showed the hydrogenation of 5 successful with high ee.

Some therapeutic uses. Used as precursors in the synthesis of (-)-sparteine analogues.4